Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.35 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23368116 | 1.00 | CYP17A1 (0.43) | CYP17A1BRAFKDRFLT1MAPK14 | |
| SCHEMBL21612809 | 0.86 | CYP17A1 (0.42) | CYP17A1BRAFKDRFLT1MAPK14 | |
| SCHEMBL29834629 | 0.85 | CYP17A1 (0.42) | CYP17A1BRAFKDRFLT1MAPK14 | |
| SCHEMBL23355451 | 0.85 | CYP17A1 (0.42) | CYP17A1BRAFKDRFLT1MAPK14 | |
| SCHEMBL29834703 | 0.85 | BRAF (0.43) | CYP17A1BRAFKDRFLT1MAPK14 | |
| SCHEMBL23355378 | 0.84 | LMNA (0.37) | KDRABL1 | |
| SCHEMBL24927736 | 0.84 | CYP17A1 (0.41) | CYP17A1BRAFKDRFLT1ABCB1 | |
| SCHEMBL29834712 | 0.84 | KDR (0.41) | CYP17A1BRAFKDRFLT1MAPK14 | |
| SCHEMBL23368031 | 0.84 | CYP17A1 (0.41) | CYP17A1BRAFKDRFLT1MAPK14 | |
| SCHEMBL24926749 | 0.82 | BRAF (0.41) | CYP17A1BRAFKDRFLT1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2022170043-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ERBB2, EGFR, ERBB4 | CYP17A1 3308/4885BRAF 16/4885KDR 48/4885 |
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | CYP17A1 599/4885BRAF 28/4885KDR 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.